We're proud to be named @GenomeWeb's 2026 Best Places to Work—for the second year in a row! This recognition is especially meaningful because it comes directly from our employees. It reflects the collaboration, shared purpose and supportive culture that bring our mission to life everyday. To our entire Lucid Diagnostics team, thank you for the dedication, passion and commitment you bring to our work and to one another. We're proud of what we've built together and excited for what's ahead. #BestPlacesToWork #Team

More than 90% of patients at risk for esophageal precancer never get screened with endoscopy. Many have been managing their heartburn with medication for years, unaware that chronic reflux can put them at risk for esophageal precancer and cancer. Without screening, these patients can go undetected until the disease has progressed. @EsoGuard_Test is helping change that. This non-endoscopic triage test helps clinicians identify which at-risk patients are more likely to have precancerous changes and may benefit most from endoscopy. The result? Better insight before endoscopy, higher diagnostic yield, and more clinically actionable findings. Connect with the Lucid Diagnostics team at #ACG2026 to learn how EsoGuard can help you identify more at-risk patients and make endoscopy more effective. #GITwitter